Cycle | Duration of severe neutropenia (days) | Placebo | Lipegfilgrastim 6 mg SC |
---|---|---|---|
1 | N | 125 | 250 |
Mean ± SD | 2.3 ± 2.5 | 0.6 ± 1.1 | |
Median (range) | 2.0 (0–11.0) | 0 (0–5.0) | |
LSM* | −1.661 | ||
95% CI* | −2.089 to −1.232 | ||
P value* | <0.0001 | ||
2 | N | 122 | 244 |
Mean ± SD | 2.2 ± 2.6 | 0.3 ± 0.7 | |
Median (range) | 1.0 (0–11.0) | 0 (0–4.0) | |
LSM* | −1.915 | ||
95% CI* | −2.317 to −1.512 | ||
P value* | <0.0001 | ||
3 | N | 122 | 245 |
Mean ± SD | 2.0 ± 2.4 | 0.4 ± 0.9 | |
Median (range) | 1.0 (0–11.0) | 0 (0–5.0) | |
LSM* | −1.640 | ||
95% CI* | −2.053 to −1.227 | ||
P value* | <0.0001 | ||
4 | N | 123 | 246 |
Mean ± SD | 2.3 ± 2.5 | 0.5 ± 1.1 | |
Median (range) | 1.0 (0–11.0) | 0 (0–0.8) | |
LSM* | −1.844 | ||
95% CI* | −2.281 to −1.407 | ||
P value* | <0.0001 |